According to the Zhitong Finance App, Hapley (002399.SZ) released its 2023 annual report. The company's operating income was 5.446 billion yuan, down 23.94% from the previous year; net loss attributable to shareholders of listed companies was 783 million yuan, which changed from profit to loss; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 780 million yuan, which changed from profit to loss; basic loss per share was 0.5338 yuan/share.

During the reporting period, the company's heparin industry chain business achieved sales revenue of RMB 4.287 billion, a year-on-year decrease of 27.15%. Pharmaceutical sales remained stable, achieving sales revenue of RMB 2,979 billion, a year-on-year decrease of 7.21%, accounting for 54.71% of the company's total revenue; gross margin increased 8.25 percentage points year-on-year to 43.58%. During the reporting period, CDMO's sales volume was approximately RMB 967 million, down 10.80% from the same period last year, and gross margin fell to 22.03%. Mainly, the end of the global public health incident and the conclusion of a high-profit service contract to provide the key enzymes needed for mRNA vaccines, which had an impact on revenue and gross margin.